SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer

Summary

A randomized phase II study to compare the efficacy and safety of SLOG or mFOLFIRINOX as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer.

Conditions

• Locally Advanced or Metastatic Pancreatic Cancer

Interventions

DRUG

S-1

Intervention is administered to patients in this Arm.

DRUG

Leucovorin(oral )

Intervention is administered to patients in this Arm.

DRUG

Gemcitabine

Intervention is administered to patients in this Arm.

DRUG

Oxaliplatin

Intervention is administered to patients in this Arm.

DRUG

Irinotecan

Intervention is administered to patients in this Arm.

DRUG

5-FU

Intervention is administered to patients in this Arm.

DRUG

Leucovorin(IV)

Intervention is administered to patients in this Arm.

Sponsors & Collaborators

• National Taiwan University Hospital

  collaborator OTHER

• Taipei Veterans General Hospital, Taiwan

  collaborator OTHER_GOV

• China Medical University Hospital

  collaborator OTHER

• National Cheng-Kung University Hospital

  collaborator OTHER

• Kaohsiung Medical University

  collaborator OTHER

• Taipei Medical University Shuang Ho Hospital

  collaborator OTHER

• Chang Gung Memorial Hospital

  collaborator OTHER

• Tri-Service General Hospital

  collaborator OTHER

• E-DA Hospital

  collaborator OTHER

• National Health Research Institutes, Taiwan

  lead OTHER

Principal Investigators

• Chen Li-Tzong · National Insitute of Cancer Research

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-03-26

Primary Completion

2019-11-30

Completion

2019-11-30

Countries

• Taiwan

Study Locations